乾癬性関節炎で生物学的製剤またはアプレミラストを 開始した患者の主要心血管イベントシルク: ナショナル レジストリ
doi: 10.1093/rheumatology/keab522
Pina Vegas and her colleagues sought to assess the relative risk of MACEs in patients with PsA initiating bDMARDs or apremilast. They found that overall, the data produced overall a positive picture regarding the incidence of MACE in treatment.